Stereotactic Radiation Therapy in Early Non–Small Cell Lung Cancer and Interstitial Lung DiseaseDavid A. Palma, Christopher J. Ryerson, Andrea Bezjak et al.|JAMA Oncology|2024Cited by 47
What is the predictive value of RECIST criteria following stereotactic lung radiation?Stephanie Gulstene, David A. Palma, Pencilla Lang et al.|Radiotherapy and Oncology|2023Cited by 19
Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic DiseaseTimothy K. Nguyen, Glenn Bauman, Sherif Ramadan et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 18
129 Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD): Primary Analysis of a Phase II TrialDavid A. Palma, Christopher J. Ryerson, Houda Bahig et al.|Radiotherapy and Oncology|2023Cited by 0